Canada’s Intellectual Property Law Firm

This article was last updated on August 5, 2020.

In view of COVID-19, we have compiled a list of important updates as it relates to the pandemic and its impact on Life Sciences.

We will continue to update this page as new updates come in:

CIPO COVID-19 updates

  • Patent, trademark and industrial design deadlines through Friday August 21, 2020 are now extended until Monday August 24, 2020 (see here, our article here, and FAQs regarding the initial extension). CIPO has indicated this will be the final extension.
  • The Patent Act was amended on March 25 to expand the powers of the Commissioner of Patents to authorize use of patented inventions in specified circumstances to respond to public health emergencies (see our article here).

How Canadian courts have changed operations due to COVID-19

  • The Federal Court of Canada (see June 25 Consolidated Practice Direction and Update #5 amended July 9, 2020) implemented a suspension period that ended on  June 15 (Western and Atlantic Canada, “WA”) / June 29 (Ontario, Quebec, and the Territories, “OQT”). Many deadlines were suspended until June 29 (WA) / July 13 (OQT) and the Court will not hold in person hearings until July 13 (WA) / July 27 (OQT).  A patent infringement trial that had commenced on March 9 but was adjourned in view of COVID-19 was ordered to resume by Zoom starting May 25 (see remote trial protocol here). See also: General Policy Statement re: Virtual Hearings and the July 21 guide COVID-19: Recommended Preventive Measures as the Court resumes certain in-person operations.
  • The Federal Court of Appeal (see March 16 , March 19 , April 2 , May 12 , May 28 , and June 11 notices) adjourned most hearings and suspended many deadlines until initially April 17 , now extended indefinitely for all files commenced before or after June 11, except for (i) Selected Files (designated primarily based on age; files will be posted on the Court’s website) and (ii) files already released from the suspension.  The Court will continue to hear appeals remotely until public advice in a particular jurisdiction allows in-person hearings.
  • Deadlines affecting intellectual property matters governed by statutes and regulations (other than the Federal Courts Act and the Federal Courts Rules ), including statutory stays under the Patented Medicines (Notice of Compliance) Regulations , have not been extended by the Federal Court/Federal Court of Appeal’s notices/Orders.
  • The status of court suspensions across Canada is available here (message from the Chief Justice of Canada).
  • An Action Committee on Court Operations in Response to COVID-19 has been established.

Health Canada's response to COVID-19

  • The Food and Drugs Act was amended on March 25 to provide regulation-making power: (i) requiring the provision of information to the Minister of Health and (ii) considered necessary “for the purpose of preventing shortages of therapeutic products in Canada or alleviating those shortages or their effects, in order to protect human health” (see our article here).
  • Health Canada has taken a number of steps to facilitate availability of COVID-19 health products, to publish information relating to COVID-19 clinical trial applications, approvals and shortages, and to provide guidance on the conduct of ongoing clinical trials in light of COVID-19 (see our articles here, here, and here). Health Canada has also contacted Health Product Licence Holders to advise how they may be able to contribute (e.g., by identifying production capacity that could be used for manufacturing personal protective equipment) and issued requests for information for alternative suppliers of certain pharmaceuticals (see our article here).  See Health Canada’s summary document regarding its various measures here. On July 28, Health Canada granted a notice of compliance with conditions to Gilead for remdesivir (VEKLURY) for the treatment of certain patients with severe symptoms of COVID-19.
  • Health Canada and the Competition Bureau have taken action against manufacturers and retailers making impermissible COVID-19 related claims (see our article here).

Other COVID-19 regulatory developments

  • There have been a number of pharmacy developments including broadening the scope of pharmacists’ practice in view of COVID-19 (see our article here).
  • Reimbursement-related developments include interim funding measures by Cancer Care Ontario, guidance by the Ontario Ministry of Health recommending a maximum 30-day supply of medication, as well as amendments in Ontario to better align calculation of brand reference price with the rest of Canada (see our article here).